Repare Therapeutics (RPTX) to Release Quarterly Earnings on Tuesday

Key Points

• Repare Therapeutics is set to announce its Q2 2025 earnings results on Tuesday, August 5th, with analysts predicting an earnings loss of ($0.56) per share and revenue of $2.50 million.
• The company’s stock recently traded at $1.55, with a market capitalization of $66.48 million and a 12-month trading range from $0.89 to $4.10.
• Acadian Asset Management LLC has raised its stake in Repare Therapeutics by 35.6%, now owning approximately 1.49% of the company, reflecting strong institutional interest as 85.09% of the stock is owned by institutional investors.

Repare Therapeutics (NASDAQ:RPTX - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($0.56) per share and revenue of $2.50 million for the quarter.

Repare Therapeutics Trading Down 0.7%

Shares of NASDAQ:RPTX traded down $0.01 on Friday, hitting $1.50. The company had a trading volume of 109,390 shares, compared to its average volume of 718,899. Repare Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.07. The business has a 50 day moving average of $1.46 and a 200 day moving average of $1.29. The company has a market cap of $64.34 million, a PE ratio of -0.50 and a beta of 0.93.

Institutional Trading of Repare Therapeutics

A hedge fund recently raised its stake in Repare Therapeutics stock. Acadian Asset Management LLC increased its holdings in shares of Repare Therapeutics Inc. (NASDAQ:RPTX - Free Report) by 35.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 640,332 shares of the company's stock after buying an additional 168,230 shares during the quarter. Acadian Asset Management LLC owned about 1.49% of Repare Therapeutics worth $624,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 85.09% of the company's stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.